Adiponectin – the new adipocyte-derived hormone with relation to obesity and insulin resistance

Česká verzia

Authors: J. Housová ¹; D. Housa ²; M. Haluzík ¹
Authors place of work: III. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA ¹; Ústav patologie 3. lékařské fakulty UK a FN Královské Vinohrady, Praha, přednosta prof. MUDr. Václav Mandys, CSc. ²
Published in the journal: Vnitř Lék 2005; 51(2): 221-225
Category: Reviews

Summary

It is generally accepted that adipose tissue is an endocrine organ producing number of hormones. These hormones play an important role in the food intake regulation and significantly affect the development of atherosclerosis and insulin resistance respectively. Adiponectin – a recently discovered adipocyte-derived hormone – is one of the most extensively studied adipocytokines. There is a growing number of both experimental and clinical evidence suggesting that adiponectin is an important ethiopathogenic factor in the development of insulin resistance, diabetes and atherosclerosis. The aim of this article is to review the current state of knowledge concerning the regulation of adiponectin production and its relationship to above mentioned diseases. The possible therapeutic potential of this hormone in the treatment of insulin resistance and/or atherosclerosis will be also discused.

Key words:
adiponectin – diabetes mellitus – insulin resistance

Zdroje

1. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372(6505): 425–432.

2. Halaas JL, Gajiwala KS, Maffei M et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269(5223): 543–546.

3. Hube F, Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999; 31(12): 626–631.

4. Juhan-Vague I, Renucci JF, Grimaux M et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20(9): 2156–2161.

5. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409(6818): 307–312.

6. Scherer PE, Williams S, Fogliano M et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270(45): 26746–26749.

7. Maeda K, Okubo K, Shimomura I et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221(2): 286–289.

8. Nakano Y, Tobe T, Choi-Miura NH et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120(4): 803–812.

9. Viengchareun S, Zennaro MC, Pascual-Le Tallec L et al. Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett 2002; 532(3): 345–350.

10. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278(11): 9073–9085.

11. Tsao TS, Murrey HE, Hug C et al. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002; 277(33): 29359–29362.

12. Tsao TS, Tomas E, Murrey HE et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003; 278(50): 50810–50817.

13. Kobayashi H, Ouchi N, Kihara S et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94(4): 27–31.

14. Combs TP, Pajvani UB, Berg AH et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004; 145(1): 367–383.

15. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762–769.

16. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105(24): 2893–2898.

17. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50(5): 1126–1133.

18. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86(8): 3815–3819.

19. Fasshauer M, Klein J, Neumann S et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290(3): 1084–1089.

20. Makimura H, Mizuno TM, Bergen H et al. Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 2002; 283(6): E1266–E1271.

21. Berg AH, Combs TP, Du X et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7(8): 947–953.

22. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930–1935.

23. Delporte ML, Funahashi T, Takahashi M et al. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 2002; 367(3): 677–685.

24. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20(6): 1595–1599.

25. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7(8): 941–946.

26. Haluzik M, Colombo C, Gavrilova O et al. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Diabetes 2003; 52(Suppl 1): A328–A328.

27. Fruebis J, Tsao TS, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98(4): 2005–2010.

28. Wang Y, Xu A, Knight C et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 2002; 277(22): 19521–19529.

29. Colombo C, Cutson JJ, Yamauchi T et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 2002; 51(9): 2727–2733.

30. Combs TP, Berg AH, Obici S et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108(12): 1875–1881.

31. Maeda N, Shimomura I, Kishida K et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8(7): 731–737.

32. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277(29): 25863–25866.

33. Ma K, Cabrero A, Saha PK et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 2002; 277(38): 34658–34661.

34. Combs TP, Wagner JA, Berger J et al. Induction of adipocyte complementrelated protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143(3): 998–1007.

35. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50(9): 2094–2099.

36. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51(10): 2968–2974.

37. Abbasi F, Lamendola C, McLaughlin T et al. Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. Metabolism 2004; 53(3): 280–283.

38. Stefan N, Bunt JC, Salbe AD et al. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 2002; 87(10): 4652–4656.

39. Ouchi N, Kihara S, Arita Y et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages.

Circulation 2001; 103(8): 1057–1063.

40. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278(4): 2461–2468.

41. Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106(22): 2767–2770.